Praecis/Amgen Abarelix-Depot Spares Patients Initial Testosterone Surge

Praecis/Amgen's abarelix-depot lowers testosterone levels in prostate cancer patients without the initial testosterone surge associated with luteinizing hormone releasing hormone agonists such as TAP's Lupron Depot, according to posters presented May 23 at the American Society for Clinical Oncology annual meeting in New Orleans.